DXCM

SEC source: 0001093557-25-000197 · wk-form4_1748465396.xml · nonDerivative · entry 1

Brown Michael Jon · CIK 0001899922 · EVP, Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,602

F1 · shares: On February 21, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $83.66 to $84.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 86,490 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 12,040 of which were granted on March 8, 2022 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000195 · wk-form4_1748376728.xml · nonDerivative · entry 1

Coleman Jon · CIK 0001442689 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,738

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in four equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000156 · wk-form4_1747080931.xml · nonDerivative · entry 1

Driscoll Rimma · CIK 0001952575 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,714

F1 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 · balance_after: Included in this number are 7,746 unvested restricted stock units, 2,672 of which were granted on August 24, 2023 and shall vest through August 24, 2026 and 5,074 of which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

SEC source: 0001093557-25-000154 · wk-form4_1747080539.xml · nonDerivative · entry 1

GALA RENEE D · CIK 0001607737 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,794

F1 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2 · balance_after: Included in this number are 10,794 unvested restricted stock units, 5,720 of which were granted on March 6, 2025 and shall vest through March 6, 2028 and 5,074 of which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

SEC source: 0001093557-25-000153 · wk-form4_1747080522.xml · nonDerivative · entry 1

Malady Kyle · CIK 0001760581 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,334

F1 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

SEC source: 0001093557-25-000152 · wk-form4_1747080510.xml · nonDerivative · entry 2

Dahut Karen M · CIK 0001533450 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 17,779

F1 · shares: Shares were transferred from direct ownership to ownership under the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, upon vesting of previously awarded restricted stock units.

F2 · ownership.nature: Shares are held by the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, with respect to which the reporting person is a trustee.

SEC source: 0001093557-25-000152 · wk-form4_1747080510.xml · nonDerivative · entry 1

Dahut Karen M · CIK 0001533450 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the WILLIAM L DAHUT, JR TRUST & KAREN M DAHUT TRUST Dated 6/14/2005, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-25-000151 · wk-form4_1747080500.xml · nonDerivative · entry 1

Heller Bridgette P · CIK 0001485616 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,043

F1 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

SEC source: 0001093557-25-000150 · wk-form4_1747080485.xml · nonDerivative · entry 3

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,046

F3 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

SEC source: 0001093557-25-000150 · wk-form4_1747080485.xml · nonDerivative · entry 2

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 39,701

F1 · shares: Shares were transferred from direct ownership to ownership under the Kirschner/Augustinos Revocable Trust, upon vesting of previously awarded restricted stock units.

F2 · ownership.nature: Shares are held by the Kirschner/Augustinos Revocable Trust, with respect to which the reporting person is trustee.

SEC source: 0001093557-25-000150 · wk-form4_1747080485.xml · nonDerivative · entry 1

AUGUSTINOS NICHOLAS · CIK 0001238485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Kirschner/Augustinos Revocable Trust, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-25-000149 · wk-form4_1747080470.xml · nonDerivative · entry 3

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,731

F3 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

SEC source: 0001093557-25-000149 · wk-form4_1747080470.xml · nonDerivative · entry 2

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 59,371

F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units.

F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.

SEC source: 0001093557-25-000149 · wk-form4_1747080470.xml · nonDerivative · entry 1

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-25-000148 · wk-form4_1747080459.xml · nonDerivative · entry 3

Collins Richard Alexander · CIK 0001700619 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,074

F3 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

SEC source: 0001093557-25-000148 · wk-form4_1747080459.xml · nonDerivative · entry 2

Collins Richard Alexander · CIK 0001700619 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 41,942

F1 · shares: Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust, upon vesting of previously awarded restricted stock units.

F2 · ownership.nature: Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.

SEC source: 0001093557-25-000148 · wk-form4_1747080459.xml · nonDerivative · entry 1

Collins Richard Alexander · CIK 0001700619 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Richard A. Collins Revocable Trust, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-25-000147 · wk-form4_1747080448.xml · nonDerivative · entry 3

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,037

F3 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

SEC source: 0001093557-25-000147 · wk-form4_1747080448.xml · nonDerivative · entry 2

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 58,630

F1 · shares: Shares were transferred from direct ownership to ownership under the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, upon vesting of previously awarded restricted stock units.

F2 · ownership.nature: Shares are held by the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, with respect to which the reporting person is a trustee.

SEC source: 0001093557-25-000147 · wk-form4_1747080448.xml · nonDerivative · entry 1

ALTMAN STEVEN R · CIK 0001191307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Steven R. and Lisa J. Altman, TTEE's Altman Family Trust DTD 8/21/92, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-25-000146 · wk-form4_1747080434.xml · nonDerivative · entry 2

TOPOL ERIC · CIK 0001468345 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Family Holdings

Disclosed balance after: 380,545

F1 · shares: Shares were transferred from direct ownership to ownership under the Topol Family Holdings, LLC, upon vesting of previously awarded restricted stock units.

F2 · ownership.nature: Shares are held by Topol Family Holdings, LLC, with respect to which the reporting person is a manager and maintains voting rights of these shares.

SEC source: 0001093557-25-000146 · wk-form4_1747080434.xml · nonDerivative · entry 1

TOPOL ERIC · CIK 0001468345 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Shares were transferred from direct ownership to ownership under the Topol Family Holdings, LLC, upon vesting of previously awarded restricted stock units.

SEC source: 0001093557-25-000224 · wk-form4a_1751919300.xml · nonDerivative · entry 1

GALA RENEE D · CIK 0001607737 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,881

F1 · shares: The original Form 4, filed on May 12, 2025, is being amended by this Form 4 to correct a calculation error that misreported the number of unvested restricted stock units granted to the reporting person on May 8, 2025. This amendment correctly reports the number of unvested restricted stock units granted to the reporting person on May 8, 2025.

F2 · shares: Represents unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

F3 · balance_after: Included in this number are 6,881 unvested restricted stock units, 5,720 of which were granted on March 6, 2025 and shall vest through March 6, 2028 and 1,161 of which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

SEC source: 0001093557-25-000083 · wk-form4_1742418120.xml · nonDerivative · entry 1

Heller Bridgette P · CIK 0001485616 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,997

F1 · shares: On February 25, 2024, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 2,618 unvested restricted stock units which were granted on May 22, 2024 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2025 Annual Meeting of Stockholders.

SEC source: 0001093557-25-000081 · wk-form4_1741987530.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,497

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000080 · wk-form4_1741987520.xml · nonDerivative · entry 1

Brown Michael Jon · CIK 0001899922 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,602

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 86,490 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 12,040 of which were granted on March 8, 2022 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000079 · wk-form4_1741987510.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,481

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000078 · wk-form4_1741987499.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,805

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000077 · wk-form4_1741987489.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 372,029

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 138,091 unvested restricted stock units, 85,490 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 34,461 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 18,140 of which were granted on March 9, 2023 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 5

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,482

F5 · price: This transaction was executed in multiple trades at prices ranging from $74.61 to $74.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F6 · balance_after: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 252 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.

SEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 4

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,609

F4 · price: This transaction was executed in multiple trades at prices ranging from $73.56 to $74.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 3

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,812

F3 · price: This transaction was executed in multiple trades at prices ranging from $72.56 to $73.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001093557-25-000066 · wk-form4_1741735060.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,527

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2 · balance_after: Included in this number are 138,091 unvested restricted stock units, 85,490 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 34,461 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 18,140 of which were granted on March 9, 2023 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000065 · wk-form4_1741735047.xml · nonDerivative · entry 2

Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,573

F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F3 · balance_after: Included in this number are 84,537 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 8,465 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 225 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.

SEC source: 0001093557-25-000065 · wk-form4_1741735047.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,775

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000064 · wk-form4_1741735035.xml · nonDerivative · entry 2

Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,981

F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F3 · balance_after: Included in this number are 74,450 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026.

SEC source: 0001093557-25-000064 · wk-form4_1741735035.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,183

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000063 · wk-form4_1741735024.xml · nonDerivative · entry 2

Brown Michael Jon · CIK 0001899922 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,602

F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F3 · balance_after: Included in this number are 86,490 unvested restricted stock units, 29,922 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 14,474 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 12,040 of which were granted on March 8, 2022 and shall vest through March 8, 2026, and 246 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on February 28, 2025.

SEC source: 0001093557-25-000063 · wk-form4_1741735024.xml · nonDerivative · entry 1

Brown Michael Jon · CIK 0001899922 · EVP, Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,804

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 2

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 142,482

F2 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting from the date of grant as follows: 1/2 shall vest on March 8, 2026, 1/8 shall vest on May 22, 2026, 1/8 shall vest on August 22, 2026, 1/8 shall vest on November 8, 2026, and the remaining balance shall vest on March 8, 2027. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000062 · wk-form4_1741735014.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,684

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000055 · wk-form4_1741640507.xml · nonDerivative · entry 1

GALA RENEE D · CIK 0001607737 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,720

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

SEC source: 0001093557-25-000019 · wk-form4_1738280669.xml · nonDerivative · entry 2

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,526

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 47,625 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025.

SEC source: 0001093557-25-000018 · wk-form4_1738280660.xml · nonDerivative · entry 2

Dolan Matthew Vincent · CIK 0001914994 · EVP, Strategy & Corporate Dev

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,044

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.

SEC source: 0001093557-25-000017 · wk-form4_1738280650.xml · nonDerivative · entry 2

Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,261

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 43,283 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025.

SEC source: 0001093557-25-000016 · wk-form4_1738280640.xml · nonDerivative · entry 2

Leach Jacob Steven · CIK 0001700255 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 268,644

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 51,972 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025.

SEC source: 0001093557-25-000015 · wk-form4_1738280630.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 319,037

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, and 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.

SEC source: 0001093557-25-000019 · wk-form4_1738280669.xml · nonDerivative · entry 1

Sylvain Jereme M · CIK 0001681267 · EVP, Chief Financal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,616

F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.

F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.

F2 · balance_after: Included in this number are 47,625 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025.

SEC source: 0001093557-25-000018 · wk-form4_1738280660.xml · nonDerivative · entry 1

Dolan Matthew Vincent · CIK 0001914994 · EVP, Strategy & Corporate Dev

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,227

F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.

F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.

F2 · balance_after: Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025, and 104 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on August 30, 2024.

SEC source: 0001093557-25-000017 · wk-form4_1738280650.xml · nonDerivative · entry 1

Stern Sadie · CIK 0001797971 · EVP, Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,354

F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.

F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.

F2 · balance_after: Included in this number are 43,283 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025.